07.09.14
A recent study published in the Journal of Clinical Psychiatry found that the multi-patented, GRAS-affirmed, standardized Ashwagandha root Sensoril was found to improve several areas of cognitive effects in subjects with bipolar disorder.
NutraGenesis is the exclusive North American sales and marketing representative for Sensoril under license from Natreon, Inc. New Brunswick, NJ.
The study was conducted at Western Psychiatric Institute and Clinic- University of Pittsburgh Medical Center. An investigational new drug application (IND) was submitted to the U.S. Food and Drug Administration and approval was obtained to use Sensoril in the study because it met FDA-approved safety guidelines.
Sixty subjects with bipolar disorder were enrolled in an eight week, double-blind, placebo-controlled study. Compared to placebo, Sensoril showed significantly greater benefits for three cognitive tasks, digit span backward, Flanker neutral response time and the social cognition response rating of the Penn Emotional Acuity Test.
“Modern research and chemistry have identified several bioactive constituents in Ashwagandha that have significant cognitive enhancing benefits, namely the steroidal lactones which are known as glycowithanolides and sitoindosides,” said Dr. Sanni Raju CEO and chairman of the Board of Natreon, Inc. “Glycowithanolides are brain antioxidants which can promote neuroprotective and memory enhancing activity.”
According to Suzanne McNeary, president and managing director for NutraGenesis, LLC, “Multi-patented, clinically proven Sensoril was the ideal test agent for this study. Sensoril is a superior, next-generation Ashwagandha extract that represents a major advancement over root-only extracts because both roots and leaves are used in Sensoril’s proprietary, water-based extraction process.” She added, “Ashwagandha leaves are naturally richer in glycowithanolide bioactive content. The unique use of leaves in addition to roots in Sensoril (based on intellectual property surrounding the extract) results in Sensoril having the highest levels of glycowithanolide bioactives (standardized to a minimum of 10%) of any commercial extract available on the market today. In addition, Sensoril is the only Ashwagandha nutraceutical sold today for which an IND has been granted as a result of Sensoril’s comprehensive safety profile and its commercial use in North America for over 12 years.”
For more information: http://sensoril.com
NutraGenesis is the exclusive North American sales and marketing representative for Sensoril under license from Natreon, Inc. New Brunswick, NJ.
The study was conducted at Western Psychiatric Institute and Clinic- University of Pittsburgh Medical Center. An investigational new drug application (IND) was submitted to the U.S. Food and Drug Administration and approval was obtained to use Sensoril in the study because it met FDA-approved safety guidelines.
Sixty subjects with bipolar disorder were enrolled in an eight week, double-blind, placebo-controlled study. Compared to placebo, Sensoril showed significantly greater benefits for three cognitive tasks, digit span backward, Flanker neutral response time and the social cognition response rating of the Penn Emotional Acuity Test.
“Modern research and chemistry have identified several bioactive constituents in Ashwagandha that have significant cognitive enhancing benefits, namely the steroidal lactones which are known as glycowithanolides and sitoindosides,” said Dr. Sanni Raju CEO and chairman of the Board of Natreon, Inc. “Glycowithanolides are brain antioxidants which can promote neuroprotective and memory enhancing activity.”
According to Suzanne McNeary, president and managing director for NutraGenesis, LLC, “Multi-patented, clinically proven Sensoril was the ideal test agent for this study. Sensoril is a superior, next-generation Ashwagandha extract that represents a major advancement over root-only extracts because both roots and leaves are used in Sensoril’s proprietary, water-based extraction process.” She added, “Ashwagandha leaves are naturally richer in glycowithanolide bioactive content. The unique use of leaves in addition to roots in Sensoril (based on intellectual property surrounding the extract) results in Sensoril having the highest levels of glycowithanolide bioactives (standardized to a minimum of 10%) of any commercial extract available on the market today. In addition, Sensoril is the only Ashwagandha nutraceutical sold today for which an IND has been granted as a result of Sensoril’s comprehensive safety profile and its commercial use in North America for over 12 years.”
For more information: http://sensoril.com
